REG - GlaxoSmithKline PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">GSK.L</Origin>
RNS Number : 6940TGlaxoSmithKline PLC16 October 2017GlaxoSmithKline plc(the'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
c)
Price(s)and
volume(s)
Price(s)
Volume(s)
15.2425
262.743
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Manufacturing & Supply
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017, on Ordinary Shares held in the Company's Deferred Investment Award Programme.
c)
Price(s)and
volume(s)
Price(s)
Volume(s)
15.2425
105.097
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, GSK Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Natureofthetransaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's Deferred Investment Award Programme.
c)
Price(s)and
volume(s)
Price(s)
Volume(s)
$40.9497
330.748
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
c)
Price(s)and
volume(s)
Price(s)
Volume(s)
15.2425
105.097
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
Senior Vice President, HR
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
c)
Price(s)and
volume(s)
Price(s)
Volume(s)
15.2425
105.097
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P J T Vallance
b)
Position/status
President, R&D
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
c)
Price(s)and
volume(s)
Price(s)
Volume(s)
15.2425
131.371
d)
Aggregatedinformation
AggregatedvolumePrice
n/a (single transaction)
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
This information is provided by RNSThe company news service from the London Stock ExchangeENDDSHKQLBFDBFEFBQ
Recent news on GSK
See all newsREG - GSK PLC - US FDA accepts new indication filing for Jemperli
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - GSK announces additional EAGLE-1 results
AnnouncementREG - GSK PLC - Results from long-term data relating to Shingrix
Announcement